Type 2 diabetes is a progressive disease, requiring treatment intensification.
May have a look at the recent article published in Diabetes journal.
TAKE-HOME MESSAGE…
* In the SUSTAIN 11 trial, the investigators compared weekly semaglutide to meal-time insulin aspart in patients with type 2 diabetes on glargine and metformin. The results showed that by the 52-week follow-up, those on semaglutide achieved 1.5% lower HbA1c than baseline compared with a 1.2% decrease within the aspart group. There was no significant difference in severe hypoglycemia between both groups. The semaglutide group on average experienced weight loss, whereas the aspart group gained weight by the 1-year follow-up.
* These findings suggest that weekly semaglutide improves HbA1c and is associated with weight loss when compared with meal-time aspart in individuals on glargine and metformin.
See Link..